Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 8/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6187376 | 0.92 | ADRB2 (0.48) | ADRB2CYP1A2CYP2C9HTR2CKDM4E | |
| SCHEMBL5585316 | 0.81 | ADRB2 (0.51) | ADRB2CYP1A2CYP2C9HTR2CADRB1 | |
| SCHEMBL5585294 | 0.80 | ADRB2 (0.62) | ADRB2CYP1A2CYP2C9HTR2CADRB1 | |
| SCHEMBL5585778 | 0.80 | ADRB2 (0.50) | ADRB2CYP1A2CYP2C9HTR2CADRB1 | |
| SCHEMBL5592434 | 0.75 | CNR2 (0.52) | ADRB2CYP1A2CYP2C9HTR2CADRB1 | |
| SCHEMBL5585313 | 0.75 | ADRB2 (0.55) | ADRB2CYP1A2CYP2C9HTR2CADRB1 | |
| SCHEMBL5585610 | 0.73 | ADRB2 (0.53) | ADRB2CYP1A2CYP2C9HTR2CADRB1 | |
| SCHEMBL29388809 | 0.73 | ADRB2 (0.97) | ADRB2CYP1A2CYP2C9HTR2CADRB1 | |
| SCHEMBL906077 | 0.73 | ADRB2 (0.97) | ADRB2CYP1A2CYP2C9HTR2CADRB1 | |
| SCHEMBL5586025 | 0.72 | ADRB2 (0.52) | ADRB2CYP1A2CYP2C9HTR2CADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1329389-C | Novel compounds and their use | BIOVITRUM AB (SE) | 2007-08-01 | — | — | CN | claimed |
| US-7229997-B2 | Compounds and their use | BIOVITRUM AB (SE) | 2007-06-12 | — | — | US | claimed |
| EP-1506185-B1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF 5-HT | BIOVITRUM AB (SE) | 2006-05-24 | — | — | EP | claimed |
| CN-1701068-A | Novel compounds and their use | BIOVITRUM AB (SE) | 2005-11-23 | — | — | CN | claimed |
| JP-2005529926-A | — | — | 2005-10-06 | — | — | JP | claimed |
| EP-1506185-A1 | NOVEL COMPOUNDS AND THEIR USE | Biovitrum AB (SE) | 2005-02-16 | — | — | EP | claimed |
| US-20030232814-A1 | Novel compounds and their use | BIOVITRUM AB (PUBL) (SE) | 2003-12-18 | — | — | US | claimed |
| WO-2003097636-A1 | NOVEL COMPOUNDS AND THEIR USE | BIOVITRUM AB (SE) | 2003-11-27 | — | — | WO | claimed |
| CN-1329389-C | Novel compounds and their use | BIOVITRUM AB (SE) | 2007-08-01 | — | — | CN | disclosed |
| US-7229997-B2 | Compounds and their use | BIOVITRUM AB (SE) | 2007-06-12 | — | — | US | disclosed |
| EP-1506185-B1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF 5-HT | BIOVITRUM AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| CN-1701068-A | Novel compounds and their use | BIOVITRUM AB (SE) | 2005-11-23 | — | — | CN | disclosed |
| EP-1506185-A1 | NOVEL COMPOUNDS AND THEIR USE | Biovitrum AB (SE) | 2005-02-16 | — | — | EP | disclosed |
| US-20030232814-A1 | Novel compounds and their use | BIOVITRUM AB (PUBL) (SE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003097636-A1 | NOVEL COMPOUNDS AND THEIR USE | BIOVITRUM AB (SE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232814-A1 | Novel compounds and their use | GPR119, FABP4, MC4R | ADRB2 63/4885CYP1A2 141/4885CYP2C9 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.